- Stocks
- Healthcare
- NASDAQ: HRTX

Price (delayed)

$18.08

Market cap

$1.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.5

Enterprise value

$1.57B

The gross margin has grown by 2.4% YoY

The quick ratio has contracted by 45% YoY and by 18% from the previous quarter

The equity has declined by 41% year-on-year and by 15% since the previous quarter

What are the main financial stats of HRTX

Market
Valuations
Earnings

Shares outstanding

91.4M

Market cap

$1.65B

Enterprise value

$1.57B

Price to earnings (P/E)

N/A

Price to book (P/B)

6.95

Price to sales (P/S)

18.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

17.73

Revenue

$88.64M

EBIT

-$229.01M

EBITDA

-$226.16M

Free cash flow

-$191.63M

Per share
Balance sheet
Liquidity

EPS

-$2.5

Free cash flow per share

-$2.11

Book value per share

$2.6

Revenue per share

$0.98

TBVPS

$3.89

Total assets

$353.56M

Total liabilities

$117.06M

Debt

$24.61M

Equity

$236.49M

Working capital

$211.69M

Debt to equity

0.1

Current ratio

3.07

Quick ratio

2.44

Net debt/EBITDA

0.36

Margins
Efficiency
Dividend

EBITDA margin

-255.2%

Gross margin

59.2%

Net margin

-256.4%

Operating margin

-257.4%

Return on assets

-54.9%

Return on equity

-75.6%

Return on invested capital

-93.3%

Return on capital employed

-91.2%

Return on sales

-258.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Heron Therapeutics stock price performed over time

Intraday

0.17%

1 week

-4.84%

1 month

2.96%

1 year

-2.11%

YTD

-14.6%

QTD

-14.6%

How have Heron Therapeutics's revenue and profit performed over time

Revenue

$88.64M

Gross profit

$52.45M

Operating income

-$228.16M

Net income

-$227.28M

Gross margin

59.2%

Net margin

-256.4%

The net margin has dropped by 83% year-on-year and by 19% since the previous quarter

HRTX's operating margin has dropped by 78% year-on-year and by 17% since the previous quarter

HRTX's revenue is down by 39% year-on-year and by 14% since the previous quarter

HRTX's gross profit is down by 38% year-on-year and by 13% since the previous quarter

What is Heron Therapeutics's growth rate over time

What is Heron Therapeutics stock price valuation

P/E

N/A

P/B

6.95

P/S

18.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

17.73

The equity has declined by 41% year-on-year and by 15% since the previous quarter

The P/B is 39% higher than the last 4 quarters average of 5.0 but 28% lower than the 5-year quarterly average of 9.6

HRTX's price to sales (P/S) is 67% less than its 5-year quarterly average of 55.9 but 40% more than its last 4 quarters average of 13.2

HRTX's revenue is down by 39% year-on-year and by 14% since the previous quarter

How efficient is Heron Therapeutics business performance

Heron Therapeutics's return on sales has shrunk by 79% YoY and by 17% QoQ

The ROIC has contracted by 37% YoY and by 20% from the previous quarter

Heron Therapeutics's ROE has decreased by 23% YoY and by 16% from the previous quarter

HRTX's ROA is down by 18% YoY and by 12% QoQ

What is HRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HRTX.

How did Heron Therapeutics financials performed over time

The quick ratio has contracted by 45% YoY and by 18% from the previous quarter

The current ratio has contracted by 38% YoY and by 15% from the previous quarter

The debt is 90% smaller than the equity

The debt to equity has soared by 100% year-on-year and by 11% since the previous quarter

The equity has declined by 41% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.